Accuray Inc. (NSDQ:ARAY) completed its $277 million acquisition of TomoTherapy Inc. (NSDQ:TOMO), tying the bow on a deal first announced in March 2010.
Oncology
Neoprobe deflects concerns over clinical trial
Cancer diagnostics company Neoprobe Corp. (NYSE Amex:NEOP) shot back at critics of the company’s latest phase 3 clinical trial of its radiopharmaceutical Lymphoseek.
“It’s clear this was the right study done the right way,” CEO Mark Pykett said during a conference call with investors and analysts to discuss the company’s first-quarter financial results.
Mela Sciences petitions FDA’s Hamburg on skin cancer device
After nearly two years of waiting for an answer from the FDA on its hand-held biopsy device for skin cancer, Mela Sciences (NSDQ:MELA) is taking to the streets.
Neoprobe dodges proxy fight with largest shareholder
Cancer diagnostics company Neoprobe Corp. (NYSE Amex:NEOP) avoided a proxy fight with its largest shareholder reaching an agreement on board nominations.
The shareholder, Platinum Montaur Life Sciences, last month threatened Neoprobe with a proxy fight aimed at installing three new directors on the Dublin, Ohio-based company’s board.
Cancer treatment: FDA approves new brain tumor treatment
A new treatment for a deadly form of brain cancer has been approved by the FDA and is cleared for sale in the U.S. market.
The NovoTTF-100A System (NovoTTF) made by NovoCure is a “non-invasive device consisting of four sets of insulated electrodes attached to an electronic box,” according to the privately-held Israeli company.
Cancer treatment merger: Accuray cashes in on TomoTherapy’s woes
Study: Hospital errors could be 10 times as high as previously thought
MASSDEVICE ON CALL — As many as a third of the people admitted to hospitals in the U.S. may fall victim to a medical error during their stay, according to a study based on data from a new hospital error tracking system.
That would make medical errors 10 times more common than previously thought, according to a report in Health Affairs.
Weight loss: Does religion make you fat?
MASSDEVICE ON CALL — Regular attendance at religious activities at a young age can mean you’re twice as likely to become obese later in life, according to a study presented at an American Heart Assn. meeting.
The study by researchers at Northwestern University found that religiously observant young adults developed a higher risk of becoming obese than more secularly oriented people.
Cancer diagnostics: With proxy fight looming, can Neoprobe deliver the goods?
As cancer diagnostics firm Neoprobe (NYSE Amex: NEOP) prepares for a potential proxy fight with Platinum-Montaur Life Sciences, the company’s largest investor, it’s worth taking a look at the Dublin, Ohio-based company’s exit potential.
Neoprobe’s largest backer gears up for proxy war
Neoprobe Corp.’s (NYSE:NEOP) largest shareholder said it’s considering launching a proxy fight aimed at installing three new directors on the cancer diagnostics company’s board.
Cancer treatment: FDA panel says benefits of Novocure’s brain tumor device outweigh the risk
A new treatment for a deadly form of brain cancer has received a favorable vote from an FDA panel, moving the device a step closer to the market.
The FDA’s neurological devices panel voted 7-to-3 with 2 abstains that there is reasonable assurance that the benefits of the NovoTTF-100A System (NovoTTF) made by NovoCure, outweigh its risks when, “administered as a monotherapy in place of standard medical therapy,” according to a prepared release from the company.